Document is current
Any future updates will be listed below
-
Authors
Usart, Marc
Kimmerlin, Quentin https://orcid.org/0000-0002-1999-782X
Stetka, Jan
Stoll, Cédric
Rai, Shivam
Almeida Fonseca, Tiago
Karjalainen, Riikka
Hao-Shen, Hui
Roux, Julien https://orcid.org/0000-0002-4192-5099
El Taher, Athimed
Lynch, Dylan https://orcid.org/0000-0001-6245-9704
Makukhin, Nikolai
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Skoda, Radek C. https://orcid.org/0000-0002-3626-9496
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 24 February 2025
First Online: 11 March 2025
Competing interests
: R.C.S. is a scientific advisor/SAB member and has equity in Ajax Therapeutics, he is a co-founder of MPNquest and he consulted for and/or received honoraria from Novartis, BMS/Celgene, AOP, GSK, Baxalta and Pfizer. M.U. is a co-founder of MPNquest. A.C. is a scientific founder and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne.
